Kymera Therapeutics
KYMR
127 hedge funds and large institutions have $1.68B invested in Kymera Therapeutics in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 45 increasing their positions, 41 reducing their positions, and 10 closing their positions.
745% more call options, than puts
Call options by funds: $22M | Put options by funds: $2.6M
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
21% more capital invested
Capital invested by funds: $1.39B → $1.68B (+$290M)
6% more funds holding
Funds holding: 120 → 127 (+7)
1.31% more ownership
Funds ownership: 101.74% → 103.05% (+1.3%)
10% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$10.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.27M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$6.62M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$5.68M |
| 5 |
Two Sigma Investments
New York
|
+$3.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.68M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$8.48M |
| 3 |
AG
Artal Group
Luxembourg
|
-$6.28M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.76M |
| 5 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$4.08M |
KYMR Hedge Fund Activity: Q1 2023 in Review
127 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q1 2023, worth a combined $1.68B — up 21% from $1.39B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KYMR positions and 10 closed out — a net gain of 7 holders — while 45 added to existing stakes and 41 trimmed.
The largest buyer was Massachusetts Financial Services, opening a new position worth an estimated $10.9M. The largest seller was Wellington Management Group, cutting an estimated $9.68M.
- 127 institutional investors held Kymera Therapeutics (KYMR) as of Q1 2023, up from 120 in Q4 2022.
- Funds reported $1.68B of Kymera Therapeutics stock for Q1 2023, up 21% quarter-over-quarter.
- 17 funds opened new Kymera Therapeutics positions in Q1 2023 and 10 closed out, a net change of +7 holders.
- The largest Kymera Therapeutics buyer in Q1 2023 was Massachusetts Financial Services, an estimated $10.9M added.
- The largest Kymera Therapeutics seller in Q1 2023 was Wellington Management Group, an estimated $9.68M sold.
Based on aggregated 13F filings for Q1 2023.